These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2770284)

  • 21. Vasoactive intestinal polypeptide stimulates cholecystokinin secretion in perfused rat duodenum.
    Funakoshi A; Nakano I; Miyazaki K
    Tohoku J Exp Med; 1989 Jan; 157(1):55-9. PubMed ID: 2711376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of lithogenic diets on mouse gallbladder epithelium. A histochemical, cytochemical and morphometric study.
    Wahlin T
    Virchows Arch B Cell Pathol; 1976 Dec; 22(4):273-86. PubMed ID: 827106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasoactive intestinal peptide in the normal and inflamed feline gallbladder.
    Jivegård L; Fahrenkrug J; Svanvik J
    Regul Pept; 1989 May; 25(2):179-85. PubMed ID: 2756154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of substance P on CCK- or VIP-induced choleresis in anesthetized dogs.
    Magnusson I; Thulin L
    Acta Physiol Scand; 1979 Jul; 106(3):293-7. PubMed ID: 41410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of fasting and refeeding on secretory granules of the mouse gallbladder epithelium. A quantitative electron microscopic study.
    Wahlin T; Bloom GD; Carlsöö B; Rhodin L
    Gastroenterology; 1976 Mar; 70(3):353-8. PubMed ID: 765187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholecystokinin downregulates receptors for vasoactive intestinal peptide and secretin in rat pancreatic acini.
    Katsushima S; Adachi H; Honda T; Sato S; Kusui T; Onishi S; Aoki E; Noguchi M; Konishi J
    Am J Physiol; 1990 Mar; 258(3 Pt 1):G395-403. PubMed ID: 2156442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of cholecystokinin with vasoactive intestinal peptide in body shaking response to ice-water immersion in rats.
    Katsuura G; Yoshikawa K; Itoh S
    Neurosci Lett; 1983 Oct; 40(3):299-302. PubMed ID: 6646503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supramaximal CCK and CCh concentrations abolish VIP potentiation by inhibiting adenylyl cyclase activity.
    Akiyama T; Hirohata Y; Okabayashi Y; Imoto I; Otsuki M
    Am J Physiol; 1998 Nov; 275(5):G1202-8. PubMed ID: 9815052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secretory behavior and ultrastructural changes in mouse gallbladder principal cells after stimulation with cholinergic and adrenergic drugs. A morphometric study.
    Axelsson H; Danielsson A; Henriksson R; Wahlin T
    Gastroenterology; 1979 Feb; 76(2):335-40. PubMed ID: 759262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of intravenous vasoactive intestinal peptide (VIP) on gallbladder function in the cat.
    Jansson R; Steen G; Svanvik J
    Gastroenterology; 1978 Jul; 75(1):47-50. PubMed ID: 401095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of ion transport in porcine gallbladder: effects of VIP and norepinephrine.
    O'Grady SM; Wolters PJ; Hildebrand K; Brown DR
    Am J Physiol; 1989 Jul; 257(1 Pt 1):C52-7. PubMed ID: 2546435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VIP-antiserum inhibits fluid secretion by the inflamed gallbladder mucosa.
    Nilsson B; Theodorsson E; Jivegård L; Thune A; Friman S; Svanvik J
    Regul Pept; 1994 Jan; 49(3):179-84. PubMed ID: 8140271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma concentrations of cholecystokinin in patients with duodenal ulcer disease.
    Fried GM; Ogden WD; Fagan CJ; Inoue K; Greeley G; Thompson JC
    Surgery; 1984 Jan; 95(1):27-33. PubMed ID: 6691183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gallbladder filling and response to cholecystokinin are not affected by vagotomy.
    Pellegrini CA; Lewin M; Patti MG; Thomas MJ; Ryan T; Way LW
    Surgery; 1985 Sep; 98(3):452-8. PubMed ID: 4035567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of vagotomy on cholecystokinin release and gallbladder contraction in patients with complicated duodenal ulcer.
    Huang YS; Huang TJ; McKay D; Rayford PL
    Eur Surg Res; 1994; 26(6):362-71. PubMed ID: 7851462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasoactive intestinal peptide augmentation of cholecystokinin-8-stimulated pepsinogen secretion: evidence for dual modulation of chief cell function.
    Ballantyne GH; Zdon MJ; Zucker KA; Tyskoff M; Fratesi GR; Schafer DE; Modlin IM
    J Surg Res; 1986 Jun; 40(6):617-23. PubMed ID: 3018365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat spinal cord.
    Yaksh TL; Abay EO; Go VL
    Brain Res; 1982 Jun; 242(2):279-90. PubMed ID: 6896838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of vagal stimulation on pancreatic secretion and on blood levels of gastrin, cholecystokinin, secretin, vasoactive intestinal peptide, and somatostatin.
    Guzman S; Chayvialle JA; Banks WA; Rayford PL; Thompson JC
    Surgery; 1979 Aug; 86(2):329-36. PubMed ID: 462378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gallbladder sensitivity to CCK in duodenal ulcer disease, highly selective and truncal vagotomy.
    Masclee AA; Jansen JB; Corstens FH; Lamers CH
    Hepatogastroenterology; 1996; 43(8):400-4. PubMed ID: 8714233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide receptor antagonists in the study of insulin and glucagon secretion in mice.
    Karlsson S; Ahrén B
    Eur J Pharmacol; 1990 Dec; 191(3):457-64. PubMed ID: 1964911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.